Vcanbio Cell & Gene Engineering Corp.,Ltd. News

Zhongyuan Xiehe (600645) First Coverage Report: The industry ushered in a cusp for rapid advancement of innovative stem cell drugs

Aug 29 00:00

Zhongyuan Xiehe (600645): Strong research and diagnostic materials help accurately diagnose high-growth cell therapy benefiting policies, the prospects for Chunfeng are attractive

方正證券Jan 28, 2022 00:00

Zhongyuan Xiehe (600645) review: Cell immunity leaders are emerging, stem cells and genes are becoming more abundant

華泰證券Apr 14, 2016 00:00

[Huatai] Vcanbio: the leader of cellular immunity is looming, stem cells and genes are becoming more and more abundant.

華泰證券Apr 13, 2016 00:00

Vcanbio (600645) comments: the first step in the initiation of epitaxial mergers and acquisitions

方正證券Mar 7, 2016 00:00

[Huatai Securities] Zhongyuan Xiehe: Collison enters arms and expands cell therapy channels

華泰證券Mar 4, 2016 00:00

Vcanbio (600645) comments: Collison embraces the expansion of cell therapy channels in Huaizhong.

華泰證券Mar 4, 2016 00:00

Vcanbio (600645) Research brief: epitaxial expansion is still promoting the gradual formation of gene cell strategy.

方正證券Feb 26, 2016 00:00

Vcanbio (600645) in-depth study: cell and gene dual-core drive "611" model deduction is wonderful

華泰證券Feb 25, 2016 00:00

Vcanbio (600645) Research report: to build the leader of the whole industry chain with "cell + gene" as the dual core

西南證券Jan 5, 2016 00:00

[southwest Securities] Vcanbio: to build the leader of the whole industry chain with "cell + gene" as the dual core

西南證券Jan 4, 2016 00:00

[Haitong] Vcanbio Company announcement comments: to build a life industry ecosystem, cell gene two-wheel drive

海通證券Dec 23, 2015 00:00

中源协和(600645)点评：打造生命产业生态系统 细胞基因双轮驱动

海通證券Dec 23, 2015 00:00

中源协和(600645)点评：精准医疗持续布局 短中长期业务布局完善

興業證券Nov 24, 2015 00:00

【兴业证券】中源协和:精准医疗持续布局,短中长期业务布局完善

興業證券Nov 23, 2015 00:00

【方正证券】中源协和:业绩符合我们预期

方正證券Apr 28, 2015 00:00

【海通证券】中源协和:细胞和基因领域战略布局排头兵

海通證券Feb 27, 2015 00:00

【方正证券】中源协和:外延并购和内生纵向扩张的新兴基因技术公司

方正證券Dec 11, 2014 00:00

[Huaxin Securities] Zhongyuan Xiehe: Acquire Zhicheng Biology to enter the field of diagnostic reagents

華鑫證券May 23, 2014 00:00

【华宝证券】ST中源:确保和泽生物并表收益,业绩未来巨幅增长

華寶證券Jan 30, 2012 00:00